March 13, 2026-
A single infusion of GS001, an investigational gene therapy, has demonstrated durable expression of factor VIII (FVIII) in patients with severe Hemophilia A, with effects lasting up to nearly three years. The therapy, which utilizes an AAV8 vector, was evaluated in a Phase 1 pilot study and showed the potential to significantly reduce bleeding episodes and the need for routine factor replacement therapy at doses lower than those used in currently approved gene therapies.
Hemophilia A is caused by mutations in the F8 gene, resulting in a deficiency of FVIII, a critical protein required for normal blood clotting. Standard treatment involves regular prophylactic infusions of FVIII to prevent bleeding. Gene therapy aims to provide a long-term solution by delivering a functional copy of the gene to liver cells, enabling endogenous production of FVIII. However, challenges such as immune responses and limited durability of expression have historically constrained the field.
GS001 was designed to address these limitations through the use of an engineered AAV8 vector carrying a shortened but functional version of the F8 gene. This design improves gene transfer efficiency while accommodating the packaging constraints associated with the relatively large F8 gene. The study, published in Signal Transduction and Targeted Therapy, evaluated both the safety and biological activity of GS001 in 12 adult male patients.
Participants received a single intravenous infusion of GS001 at either 2×10¹² or 4×10¹² vector genomes per kilogram (vg/kg), which are notably lower than doses used in approved therapies. To mitigate immune responses against the vector and transduced liver cells, patients were pretreated with immunosuppressive regimens including prednisone, with some also receiving tacrolimus.
The therapy led to rapid increases in FVIII levels, with expression detectable within the first week and peaking between five and seven weeks post-infusion. In the lower-dose cohort, FVIII levels were maintained at levels consistent with moderate hemophilia for nearly three years of follow-up. In the higher-dose group, patients achieved FVIII levels corresponding to mild hemophilia after approximately two years. These results indicate sustained transgene expression and functional activity over extended periods.
Clinical outcomes mirrored these biological improvements. Patients experienced substantial reductions in annual bleeding rates, along with decreased reliance on exogenous FVIII replacement therapy. Notably, no patients in the higher-dose group required on-demand FVIII treatment during the follow-up period, underscoring the therapy’s clinical benefit.
The study also highlighted the importance of immunosuppression in enhancing gene therapy outcomes. Patients receiving a combination of prednisone and tacrolimus showed faster increases in FVIII levels and maintained higher expression over time compared to those receiving prednisone alone. Mechanistic analyses suggested that tacrolimus effectively suppressed T cell-mediated immune responses that could otherwise limit transgene expression.
GS001 was generally well tolerated across both dose groups. The most common treatment-related adverse events were transient elevations in liver enzymes, which resolved with monitoring or short-term intervention. No serious adverse events related to the gene therapy or immunosuppressive regimen were reported.
Overall, GS001 demonstrates that AAV8-based gene therapy can achieve durable FVIII expression at significantly lower doses, potentially improving safety while maintaining efficacy. Ongoing follow-up will continue to assess the long-term durability of FVIII expression, particularly in the higher-dose cohort.
These findings support the continued development of GS001 as a promising next-generation gene therapy for hemophilia A, offering the potential for sustained disease control with a single administration.
